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Abstract
Background: YKL-40 (also known as Chitinase 3-like 1) is a glycoprotein produced by inflammatory, cancer and stem
cells. Its physiological role is not completely understood but YKL-40 is elevated in the brain and cerebrospinal fluid
(CSF) in several neurological and neurodegenerative diseases associated with inflammatory processes. Yet the precise
characterization of YKL-40 in dementia cases is missing.
Methods: In the present study, we comparatively analysed YKL-40 levels in the brain and CSF samples from
neurodegenerative dementias of different aetiologies characterized by the presence of cortical pathology and
disease-specific neuroinflammatory signatures.
Results: YKL-40 was normally expressed in fibrillar astrocytes in the white matter. Additionally YKL-40 was highly and
widely expressed in reactive protoplasmic cortical and perivascular astrocytes, and fibrillar astrocytes in sporadic
Creutzfeldt-Jakob disease (sCJD). Elevated YKL-40 levels were also detected in Alzheimer’s disease (AD) but not
in dementia with Lewy bodies (DLB). In AD, YKL-40-positive astrocytes were commonly found in clusters, often around
β-amyloid plaques, and surrounding vessels with β-amyloid angiopathy; they were also distributed randomly in the
cerebral cortex and white matter. YKL-40 overexpression appeared as a pre-clinical event as demonstrated in
experimental models of prion diseases and AD pathology.
CSF YKL-40 levels were measured in a cohort of 288 individuals, including neurological controls (NC) and patients diagnosed
with different types of dementia. Compared to NC, increased YKL-40 levels were detected in sCJD (p < 0.001, AUC = 0.92) and
AD (p < 0.001, AUC = 0.77) but not in vascular dementia (VaD) (p > 0.05, AUC = 0.71) or in DLB/Parkinson’s disease dementia
(PDD) (p > 0.05, AUC = 0.70). Further, two independent patient cohorts were used to validate the increased CSF YKL-40 levels
in sCJD. Additionally, increased YKL-40 levels were found in genetic prion diseases associated with the PRNP-D178N
(Fatal Familial Insomnia) and PRNP-E200K mutations.
Conclusions: Our results unequivocally demonstrate that in neurodegenerative dementias, YKL-40 is a disease-specific
marker of neuroinflammation showing its highest levels in prion diseases. Therefore, YKL-40 quantification might have
a potential for application in the evaluation of therapeutic intervention in dementias with a neuroinflammatory component.
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Background
YKL-40 is a glycoprotein secreted by various cell-types
including macrophages, chondrocytes, vascular smooth
muscle cells and some types of cancer cells [1–4]. In
normal adult human tissue higher YKL-40 expression is
observed in cells with high cellular activity [5]. Although
its precise function is not well understood, it is hypothe-
sized to be involved in tissue remodelling during inflam-
mation and in angiogenic processes mediating infiltration,
differentiation and maturation of macrophages, and it is
therefore considered a marker of inflammation and endo-
thelial dysfunction [6–9]. Elevated YKL-40 is reported in
many pathological conditions such as cancer, diabetes
mellitus, cardiovascular disorders and inflammatory
diseases of different aetiologies including, among
others: bacterial infections, osteoarthritis, hepatic fibrosis,
ulcerative colitis, Crohn’s disease, rheumatoid arthritis,
asthma, chronic obstructive pulmonary disease and liver
cirrhosis [4, 10–14].
In the brain, YKL-40 is upregulated in several neuro-
logical disorders such as stroke, lentiviral encephalitis,
traumatic brain injury, amyotrophic lateral sclerosis,
multiple sclerosis and Alzheimer’s disease (AD) [15–18].
Although YKL-40 was initially associated with the
macrophage lineage [19–21], evidence suggests that dur-
ing neuroinflammatory processes, its expression is abun-
dant in reactive astrocytes and residual in microglial
cells [16, 22]. Indeed, astrocytic YKL-40 expression has
been reported in both acute and chronic neurological
conditions [16] and in close vicinity to amyloid plaques
and neurofibrillary tangles in AD [23]. In CSF, YKL-40 is
elevated in several acute and chronic neuroinflammatory
conditions [16] and in preclinical and prodromal AD/
mild cognitive impairment (MCI) [23–26], which is in
agreement with the potential role of astrocytosis in early
AD pathogenesis [27]. Interestingly, YKL-40 is associated
with cerebral morphometric patterns different from
those linked to phospho-tau (p-tau)-related neurodegen-
eration [28], indicating a dissociation between astrocytic
activation and p-tau pathology in early AD. Increased
CSF YKL-40 levels have been reported in multiple AD
cohorts [29–34], and in frontotemporal dementia (FTD)
cases [34–36] but not in vascular dementia (VaD) and in
DLB/PDD [32, 35], indicating that its deregulation is as-
sociated with disease-specific alterations and further
suggesting that elevated CSF YKL-40 levels is not a spe-
cific signature for AD pathogenesis. However, conflicting
data regarding non-AD dementias has been reported
[35, 37]. Moreover, absence of studies reporting YKL-40
levels in prion diseases, which present the highest neu-
roinflammatory component among all dementia condi-
tions [38], impedes establishment of the precise accuracy
of YKL-40 quantification in the differential diagnostic
context of neurodegenerative dementias. Further, brain
YKL-40 expression patterns in different dementia types,
and the potential correlation between brain and CSF
levels is largely unknown, indicating that more research
regarding YKL-40 expression patterns is required. Based
on the data presented before, YKL-40 is in the spot light
of biomarker research.
In this study, we investigated the sources of YKL-40 in
the brain and evaluated its levels in the CSF in different
types of neurodegenerative dementias, allowing us to de-
termine the accuracy of YKL-40 quantification in the
differential diagnostic context. Our data revealed that
YKL-40 expression, while residual in the white matter of
control cases, was highly increased in reactive protoplas-
mic and perivascular astrocytes in sCJD and AD cases.
Among the different disease groups studied, highest
YKL-40 levels in brain and CSF were observed in sCJD
cases, followed by AD and DLB.
Methods
Reagents and antibodies
Detection of human YKL-40 by western blot was per-
formed using the Human Chitinase 3-like 1 Antibody
AF2599 (R&D Biosystems). Detection of murine YKL-40
by western blot, and human and murine YKL.40 by im-
munohistochemistry and immunofluorescence was per-
formed using the Chitinase 3-like 1 antibody PA5–43746
(Thermo Fisher).
Anti-GAPDH 9484, anti-β-actin 8226 and anti-
vimentin 92547 antibodies were from Abcam. Mouse
anti-GFAP MAB360 was from Millipore. Rabbit Anti-
GFAP Z0334 and anti-amyloid beta (β-amyloid) M0872
were from Dako. Anti-PrP(12F10) A03221 was from SPI
Bio. Thioflavin was from Sigma. Chimeric recombinant
prion protein (PrP), composed of the Syrian hamster resi-
dues 23–137 followed by sheep residues 141–234 (of the
R154 Q171 polymorphism), was from Thermo Fisher.
Demographics and human cases
Brain tissue was obtained from the Institute of Neuro-
pathology Brain Bank (HUB-ICO-IDIBELL Biobank) and
the Biobank of Hospital Clinic-IDIBAPS following rele-
vant guidelines of both Spanish legislation and the local
ethics committee. Neuropathological examination and
characterization were carried out on paraffin-embedded
samples in every case. Detailed information on neuropath-
ology and inflammatory profiling of the sCJD and AD co-
horts has been previously reported [39–42]. sCJD MM1
and VV2 cases were selected due to their higher preva-
lence, but different clinical phenotypes [43]. The presence
of infectious, metabolic and neoplastic diseases was ruled
out in control samples. No correlation between post-
mortem delay or sample storage time and levels of pro-
teins and mRNA analysed was observed. A full summary
of the cases is available in Additional file 1.
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In order to establish the potential diagnostic utility of
CSF YKL-40 measurement in the context of differential
diagnosis of neurodegenerative dementias, we utilized
samples from three independent cohorts: i) cases re-
cruited at the Clinical Dementia Center at the University
Medical Center Göttingen (Germany) (cohort 1), ii)
cases recruited at the Hospital Clinic de Barcelona
(Spain) (cohort 2) and iii) cases recruited at hospitals of
northern Greece that were further processed at the
Laboratory of Pharmacology (School of Pharmacy,
Aristotle University of Thessaloniki), as part of add-
itional molecular analysis to enhance disease diagnosis
(cohort 3). Lumbar puncture was performed for diagnos-
tic purposes followed by analysis of CSF standard pa-
rameters. YKL-40, tau, 14–3-3 and Aβ42 were analysed
at the point of the first diagnostic work-up. In cohort 1,
the neurological control group was composed of patients
with either clinically or pathologically defined alternative
diagnoses [44, 45]. This group included cases of psychi-
atric disorders, ischemic stroke, epilepsy, autoimmune
diseases, alcohol abuse, headache, vertigo, pain syn-
dromes, acute hypoxia and non-related neurological
conditions. Control cases did not present biomarker pro-
files indicating the presence of a neurodegenerative dis-
ease. Diagnosis of AD was based on the International
Classification of Diseases, Tenth Revision (ICD-10)
definition for AD (F.00-G.30). Rapidly progressive
Alzheimer’s disease (rpAD) was defined by a velocity of
cognitive decline >6pts/yr. on the Mini Mental Status
Examination scale [46]. Velocity of decline was calcu-
lated using linear regression (least square method) in ac-
cordance with Villemagne et al. [47]. The diagnosis of
DLB was based on the criteria of McKeith [17] and PDD
as dementia in patients with PD. VaD diagnosis was
based on ICD 10 definition (F01) and NINDS-AIREN
criteria [48]. In cohort 2, controls were neurologically
healthy individuals with no neurological clinical diagno-
sis and normal neuropsychological assessment. AD pa-
tients were diagnosed with probable AD using the
National Institute of Neurological and Communicative
Disorders and Stroke/Alzheimer’s Disease and Related
Disorders Association criteria [49] and displayed the
typical CSF biomarker profile, characteristic of AD
(low levels of amyloid beta 1–42 (Aβ42) and elevated
t-tau and p-tau levels). In cohort 3, controls were
composed of subjects with cognitive impairment/de-
mentia (of unknown kind) with excluded prion diag-
nosis. sCJD cases were classified as definite cases by
neuropathological examinations or as probable cases
according to diagnostic consensus criteria [50, 51].
Genetic prion cases were confirmed by genetic testing
(PRNP D178N and E200K mutations). Additional file 2
provides information on demographics and CSF bio-
markers results.
Experimental mouse models
As a sCJD MM1 mouse model, the tg340 mouse line ex-
pressing about 4-fold level of human PrP M129 on a
mouse PrP null background [52] was used. Control or
sCJD MM1 brain tissues were inoculated as 10% (w/v)
homogenates in 6–10 week-old mice in the right parietal
lobe using a 25-gauge disposable hypodermic needle.
Mice were observed daily and the neurological status
was assessed weekly. The animals were sacrificed at pre-
symptomatic (pre-clinical: 120 day post inoculation (dpi)
and symptomatic (early clinical: 160 dpi and late clinical:
183 dpi) stages. Additionally, sCJD MM1 inoculum dilu-
tions were performed to study prolonged disease times;
animals were sacrificed at 210 dpi (10–1 dilution). Part
of the brain was fixed by immersion in 10% buffered for-
malin to quantify spongiform degeneration and perform
immunohistological analyses. The remaining brain was
snap frozen and stored at −80 °C for protein and RNA
studies. The 5xFAD mouse line harbouring the APP
KM670/671NL (Swedish), APP I716V (Florida), APP
V717I (London), PSEN1 M146 L (A&gt;C), PSEN1
L286 V mutations was used as a model of AD pathogen-
esis. This widely-used model recapitulates several AD-
related phenotypes displaying severe amyloid pathology
and gliosis at about 2–3 months, cognitive alterations at
4–5 months and synaptic and neuronal loss at 9 of age
[53, 54]. For scrapie infections with prion strains RML
(immunohistochemical data) and 22 L (qPCR data), all
animal experiments were in strict accordance with the
principles of laboratory animal care (NIH publication
No. 86–23, revised 1985) and the recommendations in
the Guide for the Care and Use of Laboratory Animals
of the German Animal Welfare Act on protection of ani-
mals. Animals were maintained under specific pathogen-
free conditions. Mice were anesthetized with Ketamine/
Xylazin hydrochloride prior to inoculation. Eight weeks
old mice were inoculated intracerebrally (i.c.) with RML
5.0-prions (immunohistochemical data) and 22 L prions
(qPCR data). Animals were checked daily and were
taken at indicated time points or were allowed to pro-
gress to clinical prion disease (presenting with slowness,
ataxia, weight loss, trembling and ungroomed fur). For
scrapie infections with RML strain (qPCR data), all ex-
periments were performed in the animal facility of the
Neurological Department, AHEPA University Hospital.
Approximately 8–12 weeks old mice were inoculated.
Infectious material corresponding to 100 μl of 1% brain
homogenate from terminally ill RML-infected C57Bl/6
mice (104.5 × LD50) was intraperitoneally administered
in fourteen animals; ten age-matched unchallenged mice
were used as controls. RML-infected C57Bl/6 mice de-
veloped the first clinical symptoms, corresponding to ab-
normal gait, at approximately 130 days post inoculation.
More severe symptoms, including loss of muscle tone,
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hind limb weakness, ataxia, weight loss and ruffled coat,
appeared at approximately 160 days post inoculation.
Whole brain was harvested from three animals per
group at pre-clinical (120 dpi) and end-point clinical
(180 dpi) disease stages.
Organotypic slice cultures
Organotypic cerebellar slice preparations from postnatal
day 9–13 (P9–13) pups of C57BL/6JRj mice, further in-
fection with 22 L scrapie strain, sample collection and
detection of PK-resistant Prion Protein (PrPres) were
performed as described previously [55].
CSF analysis
Total tau was measured using INNOTEST™ hTAU Ag;
(Fujirebio). Levels of amyloid β1–42 (Aβ42) were measured
with an ELISA kit (INNOTEST™ AMYLOID (1–42);
Fujirebio). YKL-40 was measured using the MicroVue
YKL-40 EIA ELISA kit from Quidel following the manufac-
turer’s instructions. Protein 14–3-3 was detected with west-
ern blot as previously described [56].
RNA purification and RT-qPCR
RNA from different human and mouse brain regions
was purified using the miRVANA RNA isolation kit
following the manufacturer’s protocol. For human sam-
ples, regions utilized for RNA extraction and corre-
sponding age and gender information is summarized in
Additional file 1. RNA was extracted from the following
murine brain regions: tg340MM1-CJDMM1: cerebral
cortex, RML scrapie: whole brain, 22 L scrapie: cerebral
cortex and cerebellum. RNAs were treated with DNase
Set (Qiagen) to eliminate genomic DNA contamination.
Sample concentration was measured using a NanoDrop
2000 spectrophotometer (Thermo Scientific) and RNA
integrity was assessed based on the RNA Integrity
Number (RIN value) measured by an Agilent 2100 Bioa-
nalyzer (Agilent). RNA samples were retrotranscribed
using the High Capacity cDNA Archive kit (Applied Bio-
systems). Quantitative PCR assays were performed in
duplicates on cDNA samples, in a LightCycler® 480 Sys-
tem (Roche). The reactions were set using 20xTaqMan
Gene Expression Assays and 2xTaqMan Universal PCR
Master Mix (Applied Biosystems) and conducted under
the following conditions: 50 °C for 2 min, 95 °C for
10 min, 40 cycles at 95 °C for 15 s and 60 °C for 1 min.
Fold changes were estimated using the 2-ΔΔCT equa-
tion. Fold changes in mRNA expression were deter-
mined relative to the control cases after normalization
with housekeeping genes; statistical significances were
calculated using GraphPad Prism 6.01. As housekeeping
genes, GAPDH and GUSB as well as Gusb and Hprt
were used as in human and mouse samples respectively.
The Taqman probes used were: CHI3L1 (YKL-40) human:
Hs01072228_m1, GFAP human: Hs00909240_m1, AIF1
(IBA-1) human: Hs00741549_g1, GAPDH human: Hs039
29097_g1, GUSB human: Hs00939627_m1, Chi3l1 (YKL-
40) mouse: Mm00801477_m1, Hprt mouse: Mm0302
4075_m1, GusB mouse: Mm00446958_g1.
Western blotting
Human and mouse tissues were lysed in lysis buffer con-
taining: 100 mM Tris pH 7, 100 mM NaCl, 10 mM
EDTA, 0.5% NP-40 and 0.5% sodium deoxycolate plus
protease and phosphatase inhibitors (Sigma). Samples
were centrifuged (14,000×g for 20 min at 4 °C) and su-
pernatants were quantified for protein concentration
using the Bradford method (Biorad). Samples were
mixed with SDS-PAGE sample buffer, heated to 95 °C
for 10 min, and resolved by SDS-PAGE analysis. Gels
were transferred onto PVDF membranes, blocked and
incubated with anti-YKL-40 antibodies (1:1000 dilution)
as indicated above. Following incubation with HRP-
conjugates, species-specific secondary antibody, the
membranes were processed for specific immunodetec-
tion using the ECL reagent. GAPDH and β-actin anti-
bodies at 1:5000 dilutions were used as loading controls.
Fold changes (in arbitrary units) were determined from
densitometric analysis relative to the control cases.
Immunohistochemistry and immunofluorescence
The immunohistochemical study was performed on
4-μm thick dewaxed brain sections. Endogenous peroxi-
dases were blocked with peroxidase (Dako, Glostrup)
followed by 10% normal goat serum. Following incuba-
tion with the anti-YKL-40 antibody (diluted 1:200) at
room temperature overnight, the sections were incu-
bated with EnVision1 system peroxidase (Dako) for
15 min at room temperature. The peroxidase reaction
was visualized with diaminobenzidine (DAB) and H2O2.
Primary antibody was omitted in some sections as im-
munostaining control and no signal was detected after
incubation with the secondary antibody. Sections were
counterstained with haematoxylin. For immunofluores-
cence, 4 μm thick dewaxed sections were stained with a
saturated solution of Sudan black B (Merck, Germany)
for 15 min to block the autofluorescence of lipofuscin
granules present in cell bodies, and then rinsed in 70%
ethanol and washed in distilled water. The sections were
boiled in citrate buffer to enhance antigenicity, blocked
for 30 min at room temperature with 10% fetal bovine
serum diluted in phosphate buffered saline, and incubated
at 4 °C overnight with primary antibodies. Double-labelling
immunofluorescence was performed using a combination
of YKL-40 (1:100) and GFAP (1:200 or 1:400) antibodies or
PrP (12F10) (1:200) and either Aβ (1:50), YKL40 (1:100) or
GFAP (1:400) antibodies. After washing, the sections were
incubated with Alexa (Molecular Probes) fluorescence
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secondary antibodies (Alexa-Fluor 488 and 555 conjugated
secondary antibodies). Nuclei were stained with DRAQ5™
(Biostatus Ltd., Shepshed, UK). After washing, the sections
were mounted in Immuno-Fluore mounting medium (ICN
Biomedicals, Irvine, CA), sealed and dried overnight. Con-
focal images were acquired using a microscope Leica
DMIRE2 and Leica confocal software. Z-Stack image inter-
val was 0.5 μm. Single plane images for quantification were
obtained by Nikon Eclipse E800 microscope with ProgRes®
CapturePro 2.7.7 software (JENOPTIK). Quantification of
YKL-40 and/or GFAP positive cells was performed manu-
ally using Fiji ImageJ software in 13–15 areas per section in
3 different patients.
Immunofluorescence of frozen brain sections in
5xFAD mice was carried out as described [57]. For the
analysis of human samples, two to four cases per diag-
nostic group were used and three to four sections from
every case were analysed. For immunohistochemical
analysis upon prion infection, tissues were fixed with 4%
buffered formalin, prion infected samples were inacti-
vated by immersion in 98% formic acid for one hour,
post fixed in 4% buffered formalin overnight and proc-
essed for paraffin embedding. Sections (2 μm) were sub-
jected to staining with the CHI3L1 antibody (YKL-40,
1:100) using a Ventana Benchmark XT (Ventana,
Tuscon, Arizona, USA). Sections were incubated with
primary antibody for 1 h, anti-rabbit Histofine Simple
Stain MAX PO Universal immunoperoxidase polymer
(Nichirei Biosciences, Wedel, Germany) was used as sec-
ondary antibody. Detection of secondary antibodies and
counter staining was performed with an ultraview universal
DAB detection kit from Ventana (Ventana, Tuscon,
Arizona, USA). Representative images were taken with a
Leica DMD108 digital microscope.
Elisa
Detection of murine YKL-40 in tissue homogenates was
performed using the Mouse Chitinase 3-like 1/YKL-40
PicoKine™ ELISA Kit (Bosterbio) following the manufac-
turer’s instructions. Inter- and intra assay coefficients of
variation were below 15%. Dilution linearity tested from
neat CSF to 1:8 dilution factor. Percent linearity was 85–
112%. For the assays, CSF was diluted 1:3.
Real-time quaking induced conversion (RT-QuIC)
RT-QuIC was performed as described previously [58, 59]
with minor modifications. Briefly, 85 μl of reaction buf-
fer containing recombinant PrP (10 μg) was mixed with
15 μl of a 1:100 dilution of 10%w/v brain homogenates.
Tissues for RT-QuIC analysis were lysed in PBS 0.1%
SDS and clarified by centrifugation for 10 min at
10000×g. Reactions were set at a final volume of 100 μl
and placed in 96-well black optical bottom plates (Fisher
Scientific). Each sample was run in triplicate. Plates were
sealed and incubated in a FLUO Star OPTIMA plate
reader (BMG Labtech Ortenberg, GE) at 42 °C for 80 h
with intermittent shaking cycles, consisting of 1 min
double orbital shaking at the highest speed (600 rpm)
followed by a 1 min break.
Statistical analysis
For two-group comparisons the Mann–Whitney test
(non-parametric distribution) and unpaired t-test (para-
metric distribution) were used. In multiple comparisons,
the Kruskal–Wallis test was used. Dunn’s multiple com-
parison test was used for post-hoc analysis. Values of
p < 0.05 were considered significant. Pearson (paramet-
ric distribution) and Spearman (non-parametric distri-
bution) tests were used to detect correlations between
biomarkers, demographic data and mRNA expression
levels. Two-way ANOVA followed by Bonferroni’s post-
hoc was used in the quantification YKL-40 and GFAP
positive cells. Receiver operating characteristic (ROC)
curves and derived area under the curve (AUC;
AUC = 0.5 no discrimination and AUC = 1 perfect dis-
crimination) were calculated. The best cut-off value, sen-
sitivity and specificity were estimated based on the
Youden index [60] (point on an ROC curve providing
the best balance of both sensitivity and specificity). ROC
curves and statistical analyses were performed using the
Graph Pad Prism 6.01 software.
Genetic testing
For detection of a prion disease-associated mutation,
genetic testing was performed on genomic DNA isolated
from blood or brain tissue [61]. Informed consent for
the prion protein gene (PRNP) analysis was obtained
from each patient or legal guardian.
Results
YKL-40 expression in sCJD patients
Expression of YKL-40 was initially analysed in sCJD as
this neurodegenerative dementia presents the highest
neuroinflammatory profile, including massive gliosis [39]
and regulation of inflammatory mediators [38] compared
to other neurodegenerative dementias [38, 40]. mRNA
analysis showed that YKL-40 was highly increased in the
frontal cortex (FC) and cerebellum (CB) of sCJD sub-
types MM1 and VV2 (p < 0.001). No statistically signifi-
cant differences were observed between sCJD subtypes
in the two regions studied. Mean fold change values for
controls versus sCJD comparisons were 6.1 in the FC
and 11.5 in the CB (Fig. 1a). YKL-40 levels were normal-
ized with GAPDH, and similar results were obtained for
GUSB normalization (Additional file 3A). In agreement
with mRNA data, YKL-40 protein levels were increased
in the FC and CB of sCJD subtypes MM1 and VV2
(p < 0.001). Mean fold change values for controls versus
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sCJD comparisons were 4.5 in the FC and 4.6 in the
CB (Fig. 1b).
Further, immunohistochemistry was used for the study
of YKL-40 expression and distribution in control and
sCJD brains. YKL-40 immunoreactivity in normal brain
was restricted to fibrillar astrocytes (stellate astrocytes
with long processes) in the white matter and was in-
creased in both the cerebral cortex and white matter of
sCJD brain tissue sections compared to controls (Fig. 2a).
YKL-40 was localized predominately in reactive proto-
plasmic and perivascular astrocytes, in addition to in-
creased signal in fibrillar astrocytes of the white matter.
Increased YKL-40 immunoreactivity was also detected in
the Bergmann glia in the CB of sCJD cases (Fig. 2b). No
apparent correlation was observed between PrPSc
amorphous deposits in the CB in VV2 and YKL-40-
positive astrocytes (data not shown). Specific expression
of YKL-40 in astrocytes was confirmed by a positive
co-localization between YKL-40 and GFAP in FC
(Fig. 2c). Interestingly, double PrP-GFAP and PrP-YKL-
40 immunostaining in the FC of sCJD revealed the pres-
ence of astrocytic processes within the PrP plaque-like
deposits (Additional file 4A and 4B).
Additionally, we found a positive correlation between
mRNA levels of YKL-40 and the astrocytic marker
GFAP (p < 0.01) in the FC of sCJD cases, while no cor-
relation was observed with the microglial marker AIF1
(p > 0.05) (Fig. 2d). As positive but moderate correlation
between GFAP and YKL-40 expression levels were ob-
served, the association between YKL-40+ and GFAP+
astrocytes was further explored. Quantification of
double-labelled GFAP and YKL-40 immunoreactive
cells showed co-localization in a majority of cells
(GFAP+/YKL-40+ = 251 ± 8 cells/mm2) whereas the
number of cells showing only GFAP staining or only
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Fig. 1 YKL-40 expression in the brain tissue of sCJD and related mouse model. a RT-qPCR analysis of YKL-40 in the frontal cortex (left panel) and
cerebellum (right panel) of control, sCJD MM1 and sCJD VV2 samples. GAPDH was used for normalization. b Western blot analysis of YKL-40 in
the frontal cortex (upper panel) and cerebellum (bottom panel) of control, sCJD MM1 and sCJD VV2 samples. For normalization GAPDH was used.
Graphical representation of Western Blot data acquired from the analysis of eight samples per group. Fold changes in the expression of mRNA and protein
were determined relative to the control cases. Kruskal-Wallis and Dunn’s post-hoc tests were used to determine statistical differences. ***p < 0.001
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Fig. 2 YKL-40 expression in sCJD brain tissue. a Immunohistochemical analysis for detection of YKL-40 in the cerebral cortex and white matter of
control and sCJD cases. b Immunohistochemical analysis of YKL-40 in the cerebellum of control and sCJD cases. Brown staining corresponds to
YKL-40 staining and light blue to haematoxylin counterstaining. c Immunofluorescence analysis of YKL-40 (green) and GFAP (red) in cerebral cortex
region of sCJD. Nuclei were stained with DAPI (blue). d Correlation between the expression levels of YKL-40 and GFAP mRNA (left panel) or AIF-1
mRNA (right panel) in the frontal cortex of sCJD cases. Normalization was performed using GAPDH. Pearson test was used to determine the correlations
between mRNA expression levels







Fig. 3 (See legend on next page.)
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cells/mm2 and 3 ± 2 cells/mm2, respectively (p < 0.001)
(Additional file 5A and B).
YKL-40 expression in in vivo experimental models of
prion disease
To gain insight into the expression levels of YKL-40
in pre-clinical and early clinical sCJD stages, we took
advantage of the tg340-PRNP-129MM mouse line in-
oculated with sCJD MM1 brain homogenate, which
fully recapitulates the neuroinflammatory profile of
human patients [40]. Analysis of the mRNA levels
indicated that YKL-40 was increased at pre-clinical
(120 dpi) and early-clinical (160 dpi) disease stages
(p < 0.05). Differences between control and sCJD
MM1-inoculated animals were more significant at
clinical stages (180 dpi, p < 0.001 and 210 dpi,
p < 0.01), resembling observations in sCJD post-
mortem brains (Fig. 3a). Western blots from the
same set of inoculated animals validated the pres-
ence of elevated YKL-40 at pre-clinical (p < 0.05)
and clinical (p < 0.001) disease stages at the protein
level as well (Fig. 3b).
To ascertain whether increased YKL-40 expression
was also present in non-human prion diseases, wild-type
mice inoculated with 22 L and RML scrapie strains were
utilized. Increased YKL-40 mRNA levels were detected
in the whole brain of RML-infected animals at late pre-
clinical (120 dpi, p < 0.05) and clinical (180 dpi,
p < 0.001) stages of the disease (Fig. 3c). Immunohisto-
chemical analysis of RML-infected mice revealed the
presence of YKL-40 positive astrocytes in the hippocam-
pus and thalamus at clinical stages. In contrast to sCJD
infected mice no staining was detected in cortical re-
gions (Fig. 3d). At pre-clinical stages sparse positive
YKL-40 positive cells were detected in the thalamic nu-
clei (Fig. 3d). In contrast, mice inoculated with the 22 L
strain, which led to a faster clinical onset and a distinct
neuropathology including more cortical PrPSc depos-
ition pattern, presented increased YKL-40 mRNA levels
in the cerebral cortex at pre-clinical (p < 0.05) and clin-
ical (p < 0.001) disease stages (Fig. 3e). Additionally,
YKL-40 mRNA levels were highly increased in the cere-
bellum of 22 L infected mice (Fig. 3f ) (p < 0.001).
YKL-40 expression in ex vivo experimental models of
prion disease
The observation of increased YKL-40 in the cerebellum
of 22 L infected mice allowed to speculate that (22 L)-in-
fected cultured organotypic cerebellar slices (COCS),
which recapitulate most of the morphological and
neuropathological hallmarks associated with prion infec-
tion and serve as an excellent ex vivo tool for the study
of prion pathogenesis [55, 62], could recapitulate the al-
terations in YKL-40 expression observed in in vivo scra-
pie models. Ten weeks post-22 L infection, we detected
astrogliosis by means of vimentin and GFAP expression
(Fig. 3g). This was accompanied by positive seeding
ability of pathogenic PrP by means of RT-QuIC ana-
lysis and presence of PrPres demonstrating the pres-
ence of prion infection on the COCS (Fig. 3h). At
this time point, increased YKL-40 protein was detected in
scrapie-infected COCS compared to mock treated cells
(p < 0.01) (Fig. 3i).
YKL-40 expression in AD patients and in AD experimental
model
Compared to controls, YKL-40 mRNA levels were in-
creased in the FC of AD cases at early (AD I-III,
(See figure on previous page.)
Fig. 3 YKL-40 expression in experimental models of prion diseases. a RT-qPCR analysis of YKL-40 in the cortex of control and sCJD MM1 inoculated
tg340PRNP129MM mice at 120 dpi (pre-clinical), 160 dpi (early clinical), 180 dpi (clinical) and 210 dpi (clinical with 10–1 diluted inoculum). Four animals
per group were analyzed. Normalization was performed using Hprt. b Representative Western-blot analyses for YKL-40 immunodetection in the cortex
of control and sCJD MM1-inoculated tg340PRNP129MM mice at 120 dpi (pre-clinical) and 180 dpi (clinical). Three animals per group were analyzed.
Normalization was based on β-actin levels. Numbers indicate densitometry results from three animals per group. Unpaired t-tests were performed to
determine statistical differences. c RT-qPCR analysis of YKL-40 in the whole brain of control and RML scrapie-infected mice at pre-clinical (120 dpi) and
clinical disease (180 dpi) stages. GAPDH was used for normalization. Similar results were acquired when normalization was based on Hprt expression
levels (not shown). Unpaired t-tests were used for estimation of statistical differences. d Immunohistochemical analysis of YKL-40 expression in the
cerebral cortex, hippocampus and thalamus of control and RML scrapie-infected mice at pre-clinical (60 and 90 dpi) and clinical (150 dpi) disease
stages. Scale bar = 50 μm. Arrows indicate YKL-40 positive reactive astrocytes. Three animals per time point were used. Two sections were stained per
animal (sagittal and coronal sections were used). Brown staining corresponds to YKL-40 staining and light blue to haematoxylin counterstaining.
e RT-qPCR analysis of YKL-40 in the cerebral cortex of control and 22 L scrapie-infected mice at pre-clinical (60 dpi) and clinical (140 dpi)
disease stages. f RT-qPCR analysis of YKL-40 in the cerebellum of control and 22 L scrapie-infected mice at clinical (140 dpi) disease stages. In all
cases GAPDH was used for normalization. Similar results were obtained when Hprt was used for normalization (not shown). Unpaired t-tests were used
to determine statistical differences. g Western blot analysis of Vimentin and GFAP in control and 22 L–scrapie infected COCS. β-actin was used for
normalization. Graphic representation of densitometry analysis of five cerebellar tissues per condition is shown. Statistical differences were determined
with unpaired t-tests. h RT-QuIC analysis of control and 22 L–scrapie infected COCS. A representative graph of three cerebellar tissues per condition is
shown. All control tissues were tested negative, while all 22 L–infected tissues were tested positive (left panel); western-blot showing the presence of
PrPres in 22 L–infected cells (right panel). i ELISA analysis of YKL-40 levels in control and 22 L–scrapie infected COCS. Statistical differences were determined
with unpaired t-tests. Fold changes in the expression of mRNA and protein were determined relative to the control cases. *p < 0.05, **p < 0.01, ***p < 0.001








Fig. 4 (See legend on next page.)
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p < 0.05) and late (AD IV-VI and rpAD IV-VI,
p < 0.001) neurofibrillary tangle Braak stages (Fig. 4a).
Mean fold change values for controls versus AD com-
parisons were 1.8 for AD II-III and, 2.9 for AD IV-VI
and 3.2 for rpAD IV-VI. No differences were detected
between AD and rpAD cases (p < 0.05). YKL-40 mRNA
levels were normalized with GAPDH, and similar results
were obtained for GUSB normalization (Additional file 3B).
In agreement with mRNA data, YKL-40 expression at pro-
tein level was increased in the FC of AD IV-VI (fold
change 2.58) and rpAD IV-VI (fold change 2.59) cases
(p < 0.05) (Fig. 4b).
Moreover, YKL-40 expression was analysed by immu-
nohistochemical staining in several AD brain regions.
Increased YKL-40 expression was detected in the cere-
bral cortex, white matter and subpial layer of AD
sections compared to controls, while it remained un-
changed in the cerebellum of AD cases (Fig. 4c).
Increased expression was also detected in the temporal
cortex and throughout the hippocampus region of AD
brain sections (Fig. 4d, and Additional file 6A). YKL-40
staining was mainly detected in astrocytes, similarly to
the patterns observed in sCJD cases. In contrast with the
diffuse distribution of YKL-40-immunoreactive astro-
cytes in sCJD, YKL-40-positive astrocytes in the cerebral
cortex in AD predominated in clusters often surround-
ing a core of fibrillar β-amyloid (Fig. 4e). YKL-40-
positive astrocytes were also present around blood
vessels with β-amyloid (Fig. 4e and Additional file 6B).
Double-labelling with YKL-40 and β-amyloid antibodies
was used to demonstrate the presence of YKL-40 posi-
tive astrocytes surrounding senile and diffuse β-amyloid
plaques in the hippocampus of AD cases (Fig. 4f and
Additional file 7).
Fibrillar astrocytes in the subcortical white matter and deep
white matter were also strongly YKL-40 immunoreactive.
Specific expression of YKL-40 in GFAP-immunoreactive as-
trocytes in the cerebral cortex and white matter regions
(Fig. 4g) in AD brains was confirmed by double-labelling im-
munofluorescence and confocal microscopy. Quantitative as-
sessment of double-labelled GFAP and YKL-40 cells
indicated a significant superior number of astrocytes showing
co-localization of GFAP and YKL-40 (238 ± 23 cells/mm2),
compared to those showing only GFAP or only YKL-40 stain-
ing (28 ± 6 cells/mm2 and 17 ± 3 cells/mm2, respectively)
(p < 0.001) (Additional file 5C and D).
As an in vivo model of AD pathogenesis we used the
5xFAD mouse model. At 3 months of age, 5xFAD ani-
mals presented glial changes and amyloid plaques but do
not show clinical signs or behavioural alterations [53,
54]. At this time point, we found increased YKL-40 and
GFAP protein levels (p < 0.05) (Additional file 8A). At
immunohistochemical level, widespread astrocytic YKL-
40 expression was detected in 10-month-old 5xFAD ani-
mals, especially in the cerebral cortex and hippocampus
(Additional file 8B) as well as in the thalamus, caudate
putamen and midbrain, while sparse YKL-40 positive as-
trocytes could be detected in the molecular layer of cere-
bellum. At this stage, animals showed clear clinical and
behavioural signs.
YKL-40 in DLB
YKL-40 mRNA expression was further analysed in the
FC of DLB cases. Despite increased mean values of
YKL.40 detected in DLB and rapid forms of DLB
(rpDLB) compared to controls, no statistically significant
alterations were found between these groups (Fig. 5a).
Similarly, no differences at the protein level were de-
tected between control and DLB cases (Fig. 5b). Sparse
YKL-40-positive astrocytes were observed in the cortical
regions, white matter and subpial layer in DLB cases;
sparse clusters of YKL-40-positive astrocytes were not
uncommon due to the fact of the associated low burden
of AD-related pathology in DLB (Fig. 5c).
CSF YKL-40 in the differential diagnosis of neurodegenerative
dementias
When CSF YKL-40 was analysed in the differential diag-
nostic context of neurodegenerative dementias (cohort
1, Additional file 2), significantly higher YKL-40 levels
were detected in sCJD cases (480 ± 178 pg/mL) com-
pared to neurological controls (NC) (250 ± 77 pg/mL)
and to the other dementia groups (p < 0.001) (Fig. 6a,
Additional file 2). Compared to NC, YKL-40 was also in-
creased in AD patients (386 ± 221 pg/mL, p < 0.001)
but not in VaD (323 ± 96 pg/mL, p > 0.05) and DLB/
(See figure on previous page.)
Fig. 4 YKL-40 expression in AD brain tissue (a) RT-qPCR analysis of YKL-40 in the frontal cortex of control, AD (I-III), AD (IV-VI) and rpAD (IV-VI) samples.
GAPDH was used for normalization. Kruskal-Wallis and Dunn’s post-hoc tests were used to estimate statistical differences. b Western blot analysis of
YKL-40 in the frontal cortex of control, AD (IV-VI) and rpAD (IV-VI) samples. Normalization was based on GAPDH levels. Graphic summary of densitometry
analyses performed on western blot results acquired from 8 control, 8 AD and 6 rpAD samples. c Immunohistochemical analysis of YKL-40 in the cerebral
cortex, white matter, subpial layer and cerebellum in control and AD cases. d Immunohistochemical analysis of YKL-40 in the temporal cortex and
hippocampus in AD cases. e Immunohistochemical analysis of YKL-40+ astrocytes surrounding β-amyloid plaques (left) and in blood vessels with
amyloid angiopathy (right) in the hippocampal region of AD cases Brown staining corresponds to YKL-40 staining and light blue to haematoxylin
counterstaining. f Double-labeling immunofluorescence of YKL-40 (green) and amyloid β (red) in the hippocampus of AD. g Double-labeling
immunofluorescence of YKL-40 (green) and GFAP (red) in cerebral cortex and white matter in AD tissues. Fold changes in expression of mRNA and protein
were determined relative to the control cases. *p < 0.05, ***p < 0.001
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PDD cases (314 ± 103 pg/mL, p > 0.05). To calculate the
clinical accuracy of YKL-40 in discriminating between
dementia and NC groups, we estimated the AUC values.
As expected, the highest values were detected when
comparing NC and sCJD cases (AUC: 0.92, 95% CI:
0.87–0.96) (Fig. 6b). Using an optimal cut-off at 315 pg/
mL defined by the Youden index, an overall sensitivity of
85% and specificity of 84% could be achieved. For the
rest of the dementias AUC values were far below those
detected for sCJD cases: NC vs AD; AUC: 0.77, 95% CI:
0.68–0.84, NC vs VaD; AUC: 0.71, 95% CI: 0.60–0.84
and NC vs DLB: AUC: 0.70, 95% CI: 0.60–0.80 (Fig. 6b).
Next we explored the ability of CSF YKL-40 to discrim-
inate sCJD from the rest of dementia groups. While
YKL-40 could not discriminate sCJD from AD with high
accuracy (AUC: 0.70, 95% CI: 0.62–0.78), values were
higher for sCJD vs DLB/PDD (AUC: 0.81, 95% CI:
0.72–0.89) and sCJD vs VaD (AUC: 0.77, 95% CI:
0.67–0.88) comparisons.
Further we analysed whether YKL-40 levels could be in-
fluenced by the rate of cognitive decline and/or disease
duration. For this reason, we stratified AD cases into slow
and fast progressive AD (AD versus rpAD) and sCJD sam-
ples according to codon 129PRNP polymorphism, which
plays a role in the clinico-pathological phenotype of the
disease and, as a consequence, in disease duration [43, 63,
64]. No differences in CSF YKL-40 levels were observed
between AD (387 ± 244 pg/mL) and rpAD (384 ± 128 pg/
mL) cases or between sCJD cases according to their codon
129 polymorphism: sCJD MM (462 ± 195 pg/mL), MV
(519 ± 203 pg/mL) and VV (456 ± 79 pg/mL) (Fig. 6c, d).
Next we sought to investigate the potential correlation
between YKL-40 and tau, disease duration and age in sCJD
cases. A significant positive correlation of YKL-40 with CSF
tau was found (p < 0.05) (Fig. 7a), but no correlation of
YKL-40 levels with CSF Aβ42, disease duration and age at
disease onset was detected (p > 0.05) (Fig. 7b and c).
Validation of increased YKL-40 levels in the CSF of prion
diseases
In order to validate the presence of increased YKL-40
levels in sCJD, two independent cohorts were used. The
first validation cohort (cohort 2, Additional file 2) in-
cluded healthy controls (HC), AD and sCJD cases.
Compared to HC (226 ± 82 pg/mL), YKL-40 levels were
significantly increased in sCJD (411 ± 157 pg/mL,
p < 0.001) and AD (311 ± 113 pg/mL, p < 0.01) (Fig. 8a,
cohort 2 Additional file 2). Similar results were ob-
tained for the second validation cohort (cohort 3,
Additional file 2), where YKL-40 levels in sCJD were
significantly higher (603 ± 198 pg/mL) than those detected




Fig. 5 YKL-40 expression in DLB brain tissue. a RT-qPCR analysis of YKL-40 in the frontal cortex of control, DLB and rpDLB samples. Normalization
was based on GAPDH levels. b Western blot analysis of YKL-40 in the frontal cortex of control, DLB and rpDLB samples. Normalization was carried
out with GAPDH. Kruskal-Wallis and Dunn’s post-hoc tests were used for determination of statistical differences. c Immunohistochemical analysis
of YKL-40 in the cerebral cortex, white matter and subpial layer in DLB cases. Brown staining corresponds to YKL-40 staining and light blue to haematoxylin
counterstaining. Fold changes in expression (mRNA and protein) were determined relative to the control cases
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p < 0.01) (Fig. 8b, cohort 3 Additional file 2). Finally, we
aimed to determine the usefulness of CSF YKL-40 levels in
the discrimination of prion disease from genetic etiology.
For this purpose, we analysed genetic cases from two co-
horts and compared them with their respective controls
and sCJD groups. The study included Controls, sCJD,
gCJD PRNP-E200K and Fatal Familial Insomnia (FFI)
(PRNP-D178N mutation) cases (cohort 1 and cohort
2, Additional file 2). In both cohorts gCJD cases har-
bouring the E200K mutation showed similar YKL-40
levels compared to sCJD cases and were statistically
different from controls (p < 0.001). In contrast, YKL-
40 levels in FFI cases were lower than in sCJD cases,
but significantly higher compared to control subjects
(p < 0.05) (Fig. 9a and b and cohort 1 and cohort 2,
Additional file 2).
Discussion
Neuroinflammation in dementia has been identified as a




Fig. 6 CSF YKL-40 in the differential diagnosis of neurodegenerative dementia. a CSF YKL-40 in NC (n = 62), sCJD (n = 84), AD (n = 84), DLB/PDD
(n = 40) and VaD (n = 20) cases (cohort 1). Number of cases analyzed and statistical significance of differences between groups is indicated. Kruskal-Wallis
and Dunn’s post-hoc tests were used for estimation of statistical differences. b ROC curves for YKL-40 quantification in the differential diagnosis of dementia
groups compared to NC. In the legend, AUC values, corresponding to the area under ROC curves, and 95% confidence intervals are reported. Diagnostic
parameters (cut-off, sensitivity and specificity) are indicated for NC versus sCJD comparison. c Stratification of AD cases in slow progressive (AD) (n = 64)
and rapid progressive (rpAD) (n = 20) cases. Statistical differences were tested with Mann–Whitney test. d Stratification of sCJD cases according to
PRNP codon 129 polymorphism (MM, n = 40, MV, n = 22 and VV, n = 20). Kruskal-Wallis and Dunn’s post-hoc tests were used for statistical
differences estimation. ***p < 0.001
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potentially causative effect of neurodegeneration in
chronic profiles [65–67]. However, the precise regional
and temporal contribution of glial activation to the
pathogenic process is far from understood. Similar to
microglial activation, sustained astrocytic activation may
lead to a switch from a neuroprotective and neuro-
trophic to a neurodegenerative phenotype, increasing
neuronal vulnerability to chemokines, pro-inflammatory
cytokines and reactive oxygen species [68–70]. This is
exemplified by proteins such as S100B, which is released
from astrocytes with neurotrophic or neurotoxic effects
on neurons depending on their concentration and on
the astrocytic activation state [71, 72]. In turn, increased
expression and secretion of S100B from astrocytes may
be reflected in the CSF patterns as reported in traumatic
brain injury [73], AD [74, 75] and sCJD [76]. Conse-
quently, astrocytes are turning into a potential target for
therapeutic intervention in neurodegenerative diseases
associated with an inflammatory component [77], indi-
cating that astrocyte-associated metabolites may be po-
tential biomarkers in biological fluids. Thus, studies on
expression patterns and function of secreted, astrocytic-
(See figure on previous page.)
Fig. 7 Correlation of CSF YKL-40 levels with CSF tau levels, disease duration and age at onset. Correlation analysis between CSF YKL-40 and (a) CSF tau
levels, (b) disease duration (as time in months from disease onset to death) and (c) age at onset. The association between CSF YKL-40 and either
biomarkers or demographics parameters was investigated with the Spearman correlation. Positive correlation was detected only for CSF YKL-40
versus CSF tau comparison
a
b
Fig. 8 Independent validation of increased CSF YKL-40 level in sCJD
patients. a CSF YKL-40 levels in HC (n = 35), AD (n = 28) and sCJD
(n = 35) cases (cohort 2). Kruskal-Wallis and Dunn’s post-hoc tests
were used for statistical differences estimation. b CSF YKL-40 levels
in Cognitive Impairment/Dementia (n = 26) and sCJD cases (n = 14)
(cohort 3). Statistical differences were estimated with the Mann–Whitney














































Fig. 9 Detection of CSF YKL-40 levels in gCJD E200K and Fatal Familial
Insomnia. a CSF YKL-40 levels in gCJD E200K, Fatal Familial Insomnia
(FFI) and NC (cohort 1). b CSF YKL-40 levels in gCJD E200K, Fatal Familial
Insomnia (FFI) and HC (cohort 2). Statistical differences were determined
with Kruskal-Wallis and Dunn’s post-hoc tests. *p < 0.05, ***p < 0.001
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related molecules under pathological or stress conditions
are gaining experimental momentum.
The functional role of YKL-40 during neuroinflamma-
tion is unclear. However, a neuroprotective effect has
been assigned to YKL-40 by an in vivo study, according
to which YKL-40 knock-out mice presented more severe
neuropathology and more prominent gliosis than their
wild-type littermates in a model of controlled cortical
impact [78]. These results indicated that YKL-40 modu-
lates the neuroinflammatory response associated with
traumatic brain impact (TBI). In agreement with this,
YKL-40 knock-out mice present exacerbated experimental
autoimmune encephalomyelitis clinical scores accompan-
ied by increased lymphocytic and macrophage infiltrates
and gliosis compared to wild-type animals [79], suggesting
that YKL-40 is necessary for the proper resolution of in-
flammation. Importantly, astrocytic YKL-40 expression is
under the control of microglial stimuli since YKL-40 tran-
scription, accompanied by morphological changes and
increased migratory capacity characteristic of reactive
gliosis, is induced by the macrophage-released pro-
inflammatory mediators Interleukin-1β (IL-1β) and tumor
necrosis factor-α [22]. Interestingly, both cytokines are
highly expressed in the microglia of TBI, sCJD, AD and
related mouse models [40, 41, 80], suggesting a cross-talk
between microglial and astrocytic activation in the regula-
tion of YKL-40-mediated functions in chronic inflamma-
tory profiles associated with neurodegeneration. These
data are supported by the finding that YKL-40 expres-
sion correlates with the expression of IL-1β and
Interleukin-6 and that both cytokines are able to syner-
gistically up-regulate YKL-40 expression in primary as-
trocytes in vitro in a STAT3 dependent-manner [81],
which in turn, has been seen to be activated in the FC
of sCJD brains [40]. In this regard, it has been recently
shown that a subtype of reactive astrocytes present in
neurodegenerative diseases is induced by secreted cyto-
kines from activated microglia [82], reinforcing the sug-
gested role of astrocyte-microglia cross-talk during
neurodegeneration [83, 84].
Aiming at a better characterization of YKL-40’s role
in neurodegenerative disorders, we studied its mRNA
and protein levels and its expression in different brain
regions in several neurodegenerative conditions.
Astrocytic YKL-40 overexpression was prominent in
both sCJD and AD, in agreement with the well-
known chronic inflammatory profile of both diseases
[38]. Most of the YKL-40+ astrocytes were stained
with GFAP antibodies, both in sCJD and AD. How-
ever, a small population of astrocytes with single la-
belling for one of the two markers was also detected,
in agreement with the positive but moderate correl-
ation between GFAP and YKL-40 expression levels
detected in sCJD.
Further, the absence of YKL-40 overexpression in DLB
was in line with the corresponding low inflammatory
profile in DLB [42, 85]. Disease-specific differences were
not restricted to expression levels, but also included
regional-dependent regulation. Indeed, we demonstrated
that YKL-40 overexpression in the cerebellum is re-
stricted to sCJD and absent in AD.
Data obtained from prion models suggest a role of
YKL-40 at pre-clinical and early stages of the disease. In
RML infected mice, early prion pathology including
microglia activation, astrogliosis and PrPSc deposition
could be first detected in the thalamus, whereas hippo-
campus and cortex still remain unchanged at the micro-
scopic level. At clinical disease stages, hippocampus and
cerebellum show widespread signs of prion pathology.
This is in line with our detection of YKL-40 immunore-
activity in RML infected mice, which was abundant in
the thalamus only at preclinical time points, but was
more widespread, including hippocampus, at clinical
prion disease stages. This is supported by the elevated
levels of YKL-40 in cortical region of the sCJD model at
pre-clinical disease stage.
Incorporation of new CSF biomarkers in clinical prac-
tice not only improves current diagnostic approaches
across the disease continuum, but also provides new
tools for prognosis and evaluation of therapeutic efficacy
once disease-modifying treatments become available
[86–88]. Therefore, peripheral biomarkers mirroring
specific disease hallmarks such as neuronal/synaptic
damage, neuroinflammation and the presence of mis-
folded proteins will become useful to evaluate thera-
peutic approaches. In this regard, we demonstrated that
CSF YKL-40 patterns resemble expression levels in brain
tissue in a disease-specific manner. Additionally, we de-
tected elevated YKL-40 in the brain of early AD (Braak
stages I-III). Although data regarding elevated CSF YKL-
40 in early stages of AD are contradictory [24, 25, 89, 90],
our results support the presence of increased astrocytic
YKL-40 expression, together with a role of astrocytosis, in
early AD pathogenesis [91]. Similarly, we detected in-
creased YKL-40 in the brain of an AD mouse model and
in experimental models of prion diseases at pre-clinical
stages, supporting the presence of astrocytic alterations
before clinical onset and the usefulness of YKL-40 quanti-
fication in the detection of early pathological changes as-
sociated with neuroinflammation. Interestingly increase in
YKL-40 at pre-clinical stages (120 dpi) of the sCJD mice
model occurs when PrPres, but not synaptic damage, is
already detectable [92] [Llorens et al. 2017, submitted],
supporting the hypothesis that neuroinflammation may
precede neuronal dysfunction.
Additionally, it has recently been shown that in MCI
and pre-AD stages, APOE ε4 carriers display higher CSF
levels of YKL-40 but not of a marker of microglial
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activation, sTREM2 (soluble triggering receptor
expressed on myeloid cells 2), supporting a role of
APOE ε4 in the regulation of astroglial response in AD
pathology [93]. However, CSF from pre-sCJD stages is
not available to rule out a potential role of CSF YKL-40
as pre-clinical marker of prion diseases. In this regard,
use of in vivo prion models not only validates regional
alterations observed in human tissue, but also supports
utilization of humanized sCJD mouse models in the un-
derstanding of human pathogenesis at pre-clinical dis-
ease stages, since scrapie infected animals present strain-
specific regional alterations that differ from those de-
tected in human and mouse sCJD samples.
An interesting finding of our study is the detection of
increased CSF YKL-40 levels in FFI, supporting the idea
that astrogliosis is a common hallmark in FFI brain tis-
sue even in regions with no major pathological involve-
ment [94, 95]. In contrast, CSF surrogate markers of
neuronal damage are less sensitive in detecting FFI cases
[44, 96] as neuronal damage is restricted to thalamic
nuclei. Elevated YKL-40 levels in gCJD-E200K patients
were in line with the similar diagnostic parameters be-
tween sCJD and gCJD-E200K for other prion
biomarkers [44, 96], due to the common clinico-
pathological spectrum of gCJD-E200K and sCJD cases
[97, 98]. Despite high CSF YKL-40 levels were found in
sCJD and AD, increased YKL-40 levels have also been
detected in other neurological and psychiatric conditions
such as brain concussions [99], acute ischemic stroke
[100], suicidal ideation [101] and bipolar disorder [102],
underlining that astrocytic activation is not restricted to
neurodegenerative conditions and that neuroinflamma-
tion may play a more prominent and common role in
the etiology of neurological diseases.
Conflicting data have been reported on the correlation
of YKL-40 with markers of neurodegeneration [23, 25,
31, 32, 89] as well as with cognitive decline [28, 31, 36, 89].
The distinct correlations between different surrogate
disease markers and cognitive decline suggest that de-
mentia hallmarks may reflect different aspects of neu-
rodegeneration processes which, although potentially
associated, may provide independent information
about the pathological state of the brain tissue. In this
regard, it has been proven that, in early AD, CSF
YKL-40 is associated with a cerebral structural signature
distinct from that related to p-tau neurodegeneration [28],
even when a positive correlation between the levels of the
two biomarkers in the CSF is reported [23–25, 34].
For sCJD, the positive correlation between CSF tau
and YKL-40 suggests an association between axonal
damage and neuroinflammation. Indeed, it is well known
that inflammatory patterns in sCJD correlate with the se-
verity of the neuropathological lesions [103]. In contrast, no
correlation was detected between age and disease duration,
most likely due to the very short disease duration of sCJD
cases (mean disease duration = 7.0 ± 5.9 months).
Conclusions
Here we report, for the first time, that higher YKL-40
levels are detectable in the brain and CSF in prion dis-
eases. Further we show that CSF YKL-40 presents a
good diagnostic accuracy in the discrimination of sCJD
from NC. While YKL-40 is also elevated in AD, it failed
discriminating AD, VaD and DLB/PDD cases (AUC < 0.8).
In this regard, caution should be taken when interpret-
ing elevated CSF YKL-40 levels in the diagnostic context
of neurodegenerative dementias. However, since CSF
YKL-40 resembles astrocytic activation in brain tissue
we speculate that YKL-40 quantification may be useful
for the assessment of neuroinflammatory profiles during
therapeutic intervention.
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Additional file 1: Summary of human brain cases and regions analyzed
with qPCR, western blot and immunohistochemical analysis. Number of
cases, age (mean ± SD) and gender (number of females and males) are
indicated. (TIFF 93 kb)
Additional file 2: Summary of CSF samples from the three independent
cohorts used in this study. Sample group, number of cases, age (mean ± SD),
tau levels (pg/mL), Aβ42 levels (pg/mL), 14–3-3 positive cases and YKL-40
levels (pg/mL) are indicated. (TIFF 147 kb)
Additional file 3: YKL-40 mRNA expression in sCJD and AD using GUSB
as housekeeping gene. Validation of alterations in YKL-40 mRNA in sCJD
(A) and AD (B) cases using GUSB as qPCR housekeeping gene. (TIFF 59 kb)
Additional file 4: YKL-40-positive astrocytes associated to PrP amyloid
plaques. Immunofluorescence images obtained from double-labeling
staining with GFAP (A) and YKL-40 (B) (green) and PrP (red) antibodies in
the cortex of sCJD. Individual channels as well as merge images are shown
for two different cortical areas. (TIFF 768 kb)
Additional file 5: Quantification of YKL-40 and GFAP overlap in sCJD
and AD cases. Immunofluorescence images obtained from double-labelling
staining with GFAP (red) and YKL-40 (green) antibodies in the hippocampus
of sCJD (n = 3) (A) and AD V (n = 3) (C) cases. Individual channels as well as
merge images are shown for two different cortical areas (one cortical image
per CJD or AD patient) of two different patients. Quantifications of GFAP
+/YKL-40+ (YKL-40-GFAP), GFAP+/YKL-40- (GFAP) and GFAP−/YKL-40+
(YKL-40) astrocytes are shown. Statistical significance differences were
detected between YKL-40-GFAP and YKL-40, GFAP groups; ###p < 0.001
and ***p < 0.001, respectively. (TIFF 5257 kb)
Additional file 6: YKL-40 expression in AD. (A) YKL-40 expression in astrocytes
in the dentate gyrus of AD. (B) Immunohistochemical analysis of YKL-40+
astrocytes surrounding β-amyloid plaques in AD cases. (TIFF 989 kb)
Additional file 7: YKL-40 positive astrocytes associated to β-amyloid
plaques. Confocal Z-stack images obtained from double-labelling staining
with YKL-40 (green) and β-amyloid (red) antibodies in the hippocampus
of AD tissue. Z-stacks from representative senile β-amyloid plaque (A)
and diffuse amyloid plaque (B) is shown. DRAQ5 staining is shown in blue.
Individual channels as well as merge images are shown. Distance between-Z
Stacks sections = 0.5 μm. (ZIP 2287 kb)
Additional file 8: YKL-40 expression in 5xFAD mice. (A) Western blot
analysis of YKL-40 and GFAP in the cortex of 3-month-old control and
5xFAD animals. Four animals per group were analyzed. GAPDH was used
for normalization. Numbers represent the summary of densitometric analysis.
Unpaired t-test was used for statistical differences estimation. (B)
Immunofluorescence analysis of YKL-40 (green) in the cerebellar cortex and
Llorens et al. Molecular Neurodegeneration  (2017) 12:83 Page 17 of 21
hippocampus of 10-month-old 5xFAD mice. Nuclei were stained with DAPI
(blue). Three animals per group and three sections per animal were analyzed.
(TIFF 235 kb)
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